Ann: Telix Q1 2024 Revenue and Business Update, page-98

First 98 Last

Share
Profile

Follow
spnc

2,089 Posts.

538

19/04/24

16:22

Post #: 73429636
Share

Originally posted by mnbvcxz12345: ↑

maybe she'll get a job with TLX

next 3 months really interesting

will be 3 months until we hear about the next quarter and if the 18% growth has been maintained ?
prob see Approvals EU and UK

FDA approvals will be a stone throw away on Zircaix
and the biggie - data readout mid year ProstAct Global cold be just weeks away

im seeing money coming out of stocks all across the board but not TLX - the past 2 weeks really, and hay, it could prob be justified to take some profit off the table on TLX for some bigger boys

maybe that spring just can't be held down anymore.

and i look at that UBS report, without going into details, looks to me like they are using some very conservative numbers for TLX for next couple years. minimal priced in for Zircaix, nothing for approvals ex USA and zero for therapy data readouts.

yet they still value TLX at $19.30

watch this space

Expand

Yeah.

Quoting you from a couple months ago:

'Zircaix (No Known Competition) AUD $1B'

Pixclara AUD $500M ($100m initially, couple years ramp up)'

Added to AUD $800M (conservative IMO) for illuccix US as per 2024E UBS

Not even counting Illuccix EMEA (speculative until approval)

So based on Illuccix US only ($800M), UBS > PT $19.5

Lets add only a fraction of Zircaix for 2024 - say AUD $400M - and PT 2024E will in fact become $30 on the day of approval.

TLX Price at posting: $13.61 Sentiment: Buy Disclosure: Held
10 Upvote

3 Great analysis

Reply